Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report.
This study used standard gamble (SG) utility interviews to assess parent preferences for health states of childhood attention-deficit/hyperactivity disorder (ADHD). Health state utilities are needed to calculate quality-adjusted life years (QALYs), a critical outcome measure in cost-effectiveness studies of new treatments. Parents (n = 43) of children diagnosed with ADHD completed SG utility interviews, rating their child's current health and 11 hypothetical health states describing untreated ADHD and ADHD treated with a stimulant or non-stimulant. Parents completed questionnaires on their children's symptoms and health-related quality of life (HRQL). Parents' SG rating of their child's current health state (mean of 0.74 on a utility scale ranging from 0 to 1) was significantly correlated with inattentive, hyperactive, and overall ADHD symptoms (r = 0.37, 0.36, and 0.40 respectively; p < 0.05) and psychosocial HRQL domains. Hypothetical health state utilities ranged from 0.48 (severe untreated ADHD) to 0.88 (effective and tolerable non-stimulant treatment). Comparisons between health states found expected differences between untreated mild, moderate, and severe ADHD health states. When both treatments were effective and tolerable, parents preferred the non-stimulant health state over the stimulant health state (p < 0.03). Results suggest that parent SG interviews are a feasible and useful method for obtaining utility scores that can be used in cost-effectiveness models of ADHD treatment.
Matza
Louis S
LS
MEDTAP International, Inc., Center for Health Outcomes Research, Bethesda, MD 20814, USA. matza@medtap.com
Secnik
Kristina
K
Rentz
Anne M
AM
Mannix
Sally
S
Sallee
F Randy
FR
Gilbert
Donald
D
Revicki
Dennis A
DA
D000328:Adult; D000704:Analysis of Variance; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000145:classification / Q000188:drug therapy / Q000523:psychology*; D002648:Child; D002652:Child Behavior; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D010290:Parents; D011437:Propylamines / Q000627:therapeutic use; D012720:Severity of Illness Index; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires
D011437:Propylamines; D000069445:Atomoxetine Hydrochloride